Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06745804 · ClinicalTrials.gov registry record · Phase 1
Study of 68Ga-R10602
A Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer, sponsored by Radionetics Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 6
- Study locations
NCT06745804: Recruiting Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer, sponsored by Radionetics Oncology.
NCT06745804 is a Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer that is actively recruiting participants, run by Radionetics Oncology. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06745804, a Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer, is actively recruiting participants, sponsored by Radionetics Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 6
- Study locations
Study Summary
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Primary Outcome
Number of participants with adverse events as assessed by NCI-CTCAE v5.0, including grade
Conditions Studied
Interventions
- DRUG 68Ga-R10602 injection
Study Locations (6)
California
- UCLA Department of Medicine - Hematology/Oncology - Los Angeles
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Iowa
- University of Iowa - Iowa City
Michigan
- University of Michigan Medicine - Ann Arbor
Texas
- MD Anderson Cancer Center - Houston
Utah
- University of Utah, Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-12-10 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT06745804 shows while recruiting
NCT06745804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 3 conditions, with Locoregionally Recurrent Hormone-receptor Positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-R10602 injection is the first listed.
NCT06745804 lists 6 locations in 6 states (California, Indiana, Iowa).
Frequently Asked Questions
What is clinical trial NCT06745804 about?
NCT06745804 is a clinical study titled "Study of 68Ga-R10602". A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
What is the current status of trial NCT06745804?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2024-12-10. Estimated completion is 2026-07.
What conditions does trial NCT06745804 study?
This clinical trial studies the following conditions: Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma.
What interventions are being tested in trial NCT06745804?
The interventions under investigation include: 68Ga-R10602 injection (DRUG).
Who is sponsoring clinical trial NCT06745804?
This trial is sponsored by Radionetics Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06745804 being conducted?
This trial has 6 study locations across California, Indiana, Iowa, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06745804's enrollment target sits among peer trials
36 1211th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI